Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study

Aims: To determine the clinical efficacy, adverse events and side-effect dyspnea of CYP3A4*22 and CYP3A5 expressor status in ticagrelor treated patients.Methods and results: Ticagrelor treated patients from the POPular Genetics randomized controlled trial were genotyped for CYP3A4*22 and CYP3A5*3 al...

Full description

Bibliographic Details
Main Authors: Jaouad Azzahhafi, Thomas O. Bergmeijer, Wout W. A. van den Broek, Dean R. P. P. Chan Pin Yin, Senna Rayhi, Joyce Peper, Willem L. Bor, Daniel M. F. Claassens, Ron H. N. van Schaik, Jurriën M. ten Berg
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
acute coronary syndrome
ticagrelor
genetic testing
myocardial infarction
percutaneous coronary intervention
pharmacogenetics
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1032995/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1032995/full

Similar Items